Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bintrafusp alfa in advanced urothelial cancer
NCT04349280Phase 1Terminated
- Sponsor
- GSK
- Start
- Oct 2020
- Primary completion
- Aug 2022
- Modality
- Immune Checkpoint Inhibitors, Fc-Fusion Proteins
- Countries
- 5
01
Overview
Phase 1, open-label, single-arm trial of bintrafusp alfa in urothelial carcinoma (UC), sponsored by GSK. Primary endpoint: Confirmed Overall Response Rate. Started Oct 2020; status: terminated.
02
Drugs
bintrafusp alfa
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT04349280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04349280.